巴曲亭及其有效成分对出血性疾病患者凝血功能的影响  

in vitro Effects of Hemocoagulase Atrix and Its Effective Components on Blood Coagulation of Patients with Bleeding Disorders

作　　者：王瑞娟[1] 王兆钺[1] 江明华[1] 张威[1] 曹丽娟[1] 孙雄华[1] 张剑[1] 白霞[1] 阮长耿[1] 

机构地区：[1]苏州大学附属第一医院、江苏省血液研究所卫生部血栓与止血重点实验室,江苏苏州215006

出　　处：《中国实验血液学杂志》2012年第2期376-380,共5页Journal of Experimental Hematology

基　　金：国家自然科学基金资助项目(编号81070395);江苏高校优势学科建设工程资助项目(PAPD)

摘　　要：本研究旨在观察巴曲亭及其有效成分的止血机理及对出血性疾病凝血功能的影响。采用全自动血凝仪检测巴曲亭及其有效成分巴曲酶与凝血因子Ⅹ激活物(FⅩA)对正常人及出血性疾病患者血浆的活化部分凝血活酶时间(APTT)与凝血酶原时间(PT)的影响,用发色底物法检测FⅩA、巴曲酶及巴曲亭对凝血因子Ⅹ(FⅩ)活化及凝血酶生成的影响。结果表明:巴曲亭及其有效成分可以缩短正常人血浆的APTT,其中FⅩA缩短APTT的作用在一定浓度范围内存在量效关系(r=0.889,P<0.05)。FⅩA、巴曲酶及巴曲亭可纠正出血性疾病患者APTT的延长,三者对PT无明显影响。FⅩA能促进FⅩ的活化及凝血酶的生成,巴曲酶及巴曲亭对二者无明显作用。结论:巴曲亭有明显的促进凝血效果,并可纠正出血性疾病的止血异常,其有效成分巴曲酶直接作用于纤维蛋白原,而FⅩA通过活化FⅩ促使凝血酶的生成。This study was aimed to investigate the procoagulation effects of hemocoagulase atrix and its effective components（batroxobin and factor Ⅹ activator） on plasma of normal subjects and patients with bleeding disorders and their mechanisms.Activated partial thromboplastin time（APTT） and prothrombin time（PT） were measured.The factor（F）Ⅹ activation and thrombin generation were analyzed by using chromogenic substrate method.The results showed that the plasma APTT of normal subjects was shortened by hemocoagulase atrix,batroxobin and FⅩ activator,and the effect of FⅩ activator was found to be concentration-dependent（r=0.889,P0.05）.The prolonged APTT of plasma from patients with bleeding disorders could be corrected by hemocoagulase atrix,batroxobin and FⅩ activator,but PT showed no great changes resulted from the treatments.FⅩ activator could promote FⅩ activation and thrombin generation,while neither hemocoagulase atrix nor batroxobin showed such abilities.It is concluded that hemocoagulase atrix promotes coagulation process,and corrects coagulation abnormalities in patients with bleeding disorders,its main component batroxobin directly acts on fibrinogen,and FⅩ activator promotes thrombin generation through activating FⅩ.

关 键 词：巴曲亭 凝血作用 出血性疾病 

分 类 号：R554[医药卫生—血液循环系统疾病]